The Access to Advanced Health Institute receives $18 million award to develop a temperature stable, single-dose chikungunya RNA vaccine through a phase 1 clinical trial
The Access to Advanced Health Institute Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine Through a Phase 1 Clinical Trial
KEY POINTS:
The goal of the award is to develop an effective chikungunya vaccine candidate that can reach endemic areas of the world by using AAHI’s innovative RNA platform technology.
The project will demonstrate that classic large-scale manufacturing challenges of live-attenuated vaccines can be overcome by using standard manufacturing equipment and techniques that are easy to tech transfer and scale.
The award supports a first-in-human clinical trial of a dried (lyophilized) ...










